HomeCompareSNNAQ vs CL

SNNAQ vs CL: Dividend Comparison 2026

SNNAQ yields 2000000.00% · CL yields 2.44%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SNNAQ wins by $1.6247481716182984e+23M in total portfolio value
10 years
SNNAQ
SNNAQ
● Live price
2000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.6247481716182984e+23M
Annual income
$147,608,011,402,949,780,000,000,000,000.00
Full SNNAQ calculator →
CL
CL
● Live price
2.44%
Share price
$85.23
Annual div
$2.08
5Y div CAGR
28.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$41.0K
Annual income
$5,451.69
Full CL calculator →

Portfolio growth — SNNAQ vs CL

📍 SNNAQ pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSNNAQCL
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SNNAQ + CL cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SNNAQ pays
CL pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SNNAQ
Annual income on $10K today (after 15% tax)
$170,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$125,466,809,692,507,310,000,000,000,000.00/yr
CL
Annual income on $10K today (after 15% tax)
$207.44/yr
After 10yr DRIP, annual income (after tax)
$4,633.94/yr
At 15% tax rate, SNNAQ beats the other by $125,466,809,692,507,310,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SNNAQ + CL for your $10,000?

SNNAQ: 50%CL: 50%
100% CL50/50100% SNNAQ
Portfolio after 10yr
$8.123740858091492e+22M
Annual income
$73,804,005,701,474,890,000,000,000,000.00/yr
Blended yield
90.85%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on CL right now

SNNAQ
Analyst Ratings
1
Buy
1
Hold
Consensus: Buy
Altman Z
-9.5
Piotroski
2/9
CL
Analyst Ratings
17
Buy
24
Hold
2
Sell
Consensus: Hold
Price Target
$92.45
+8.5% upside vs current
Range: $85.00 — $100.00
Altman Z
4.5
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SNNAQ buys
0
CL buys
9
PoliticianChamberTickerTypeAmountDate
John Boozman🏛 Senate$CL▼ Sell$1,001 - $15,0002025-10-09
Ro Khanna🏢 House$CL▼ Sell$1,001 - $15,0002025-10-07
Rick Larsen🏢 House$CL▼ Sell$1,001 - $15,0002025-10-06
Ro Khanna🏢 House$CL▼ Sell$1,001 - $15,0002025-09-29
Julie Johnson🏢 House$CL▼ Sell$1,001 - $15,0002025-09-25
Lisa McClain🏢 House$CL▼ Sell$1,001 - $15,0002025-09-11
Tim Moore🏢 House$CL▼ Sell$1,001 - $15,0002025-09-10
Ro Khanna🏢 House$CL▲ Buy$1,001 - $15,0002025-09-05
Ro Khanna🏢 House$CL▲ Buy$1,001 - $15,0002025-08-26
Lisa McClain🏢 House$CL▲ Buy$1,001 - $15,0002025-08-13
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSNNAQCL
Forward yield2000000.00%2.44%
Annual dividend / share$2.00$2.08
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%28.6%
Portfolio after 10y$1.6247481716182984e+23M$41.0K
Annual income after 10y$147,608,011,402,949,780,000,000,000,000.00$5,451.69
Total dividends collected$1.6146053563276882e+23M$18.1K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyHold

Year-by-year: SNNAQ vs CL ($10,000, DRIP)

YearSNNAQ PortfolioSNNAQ Income/yrCL PortfolioCL Income/yrGap
1← crossover$100,010,700$100,000,000.00$11,014$313.84+$100.00MSNNAQ
2$467,446,731,075$467,339,719,626.17$12,200$415.44+$467446.72MSNNAQ
3$1,021,215,363,816,662$1,020,715,195,814,411.90$13,607$553.09+$1021215363.80MSNNAQ
4$1,043,112,617,104,109,200$1,042,019,916,664,825,300.00$15,301$741.41+$1043112617104.09MSNNAQ
5$498,482,143,759,731,400,000$497,366,013,259,430,040,000.00$17,374$1,002.00+$498482143759731.38MSNNAQ
6$111,599,275,650,097,780,000,000$111,065,899,756,274,860,000,000.00$19,958$1,367.44+$111599275650097776.00MSNNAQ
7$11,738,678,336,351,557,000,000,000$11,619,267,111,405,953,000,000,000.00$23,243$1,887.87+$11738678336351557632.00MSNNAQ
8$583,674,362,697,175,100,000,000,000$571,113,976,877,278,900,000,000,000.00$27,512$2,642.43+$583674362697175072768.00MSNNAQ
9$13,894,210,989,607,547,000,000,000,000$13,269,679,421,521,570,000,000,000,000.00$33,197$3,759.22+$1.3894210989607547e+22MSNNAQ
10$162,474,817,161,829,840,000,000,000,000$147,608,011,402,949,780,000,000,000,000.00$40,973$5,451.69+$1.6247481716182984e+23MSNNAQ

SNNAQ vs CL: Complete Analysis 2026

SNNAQStock

Sienna Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs in various therapeutic areas. It develops therapies in immunology and inflammation that target select pathways in tissues, such as skin. The company's lead product candidates include SNA-120, a first-in-class inhibitor of tropomyosin receptor kinase A, which is in a Phase IIb clinical trial for the treatment of psoriasis and associated pruritus; and SNA-125, a topical dual Janus kinase 3 inhibitor that is in Phase I/II clinical trials for the treatment of atopic dermatitis, psoriasis, and pruritus. It also develops SNA-001, a topical suspension of silver particles, which is in pivotal clinical trials for the treatment of acne, as well as for the reduction of light-pigmented hair, including white, gray, blonde, light brown, and light red hair. The company was formerly known as Sienna Labs, Inc. and changed its name to Sienna Biopharmaceuticals, Inc. in February 2016. Sienna Biopharmaceuticals, Inc. was founded in 2010 and is headquartered in Westlake Village, California. On December 18, 2019, Sienna Biopharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 was converted to Chapter 7. It had filed for Chapter 11 bankruptcy on September 16, 2019.

Full SNNAQ Calculator →

CLConsumer Staples

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products worldwide. The company operates through two segments, Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items. This segment markets and sells its products under various brands, which include Colgate, Darlie, elmex, hello, meridol, Sorriso, Tom's of Maine, Irish Spring, Palmolive, Protex, Sanex, Softsoap, Lady Speed Stick, Speed Stick, EltaMD, Filorga, PCA SKIN, Ajax, Axion, Fabuloso, Murphy, Suavitel, Soupline, and Cuddly to a range of traditional and eCommerce retailers, wholesalers, and distributors. It also includes pharmaceutical products for dentists and other oral health professionals. The Pet Nutrition segment offers pet nutrition products for everyday nutritional needs under the Hill's Science Diet brand; and a range of therapeutic products to manage disease conditions in dogs and cats under the Hill's Prescription Diet brand. This segment markets and sells its products through pet supply retailers, veterinarians, and eCommerce retailers. Colgate-Palmolive Company was founded in 1806 and is headquartered in New York, New York.

Full CL Calculator →
📬

Get this SNNAQ vs CL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SNNAQ vs SCHDSNNAQ vs JEPISNNAQ vs OSNNAQ vs KOSNNAQ vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.